Background Cancer and cancer therapies have been associated with an increased
incidence of venous thromboembolic events (VTE). However, the incidence of VTE in …

Background Venous thromboembolism (VTE) is known to complicate several classes of anti-
cancer therapies including chemotherapy and anti-angiogenic agents. Immunotherapy is a …

Introduction: Cancer is known to cause a hypercoagulable state predisposing to venous
thromboembolism (VTE). In a retrospective study by Lyman et al., the incidence of VTE 3.5 …

Purpose Venous thromboembolism (VTE) is a significant cause of morbidity and mortality in
cancer patients. However, the association of VTE with immunotherapy remains poorly …

Abstract Purpose Immune Checkpoint Inhibitors (ICI) can be associated with thrombotic
events, both venous and arterial (VTE/AT). However, there is a paucity of information …

Background Immune checkpoint inhibitors (ICIs) have revolutionized the management of
cancers. The risk factors and pathophysiological mechanisms of venous thromboembolic …

Background Venous thromboembolism (VTE) is a major cause of death in cancer patients.
Although patients with cancer have numerous risk factors for VTE, the relative contribution of …

Background Prospective investigation on cancer-associated venous thromboembolism
(VTE) in non-small cell lung cancer (NSCLC) during treatment with immune checkpoint …

Background Cancer immunotherapy is associated with several immune-related adverse
events, but the relationship between immunotherapy and venous thromboembolism has not …

Venous thromboembolism (VTE) is a clinical disease that includes deep vein thrombosis
and pulmonary embolism. Amongst its underlying risk factors, cancer is of great importance …